Using vaginal laser and gel to treat genitourinary syndrome in cancer patients
Combinación Del láser Vaginal Con un Gel Niosomal Hidratante y Reparador en el Tratamiento Del síndrome Genitourinario en Pacientes oncológicas
This study is testing a new treatment using a vaginal laser and moisturizing gel to help women with genitourinary syndrome who can't use hormone therapy due to a history of cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Hospital Universitari de Bellvitge Academic / other |
| Locations | 1 site (L'Hospitalet de Llobregat, Catalonia) |
| Trial ID | NCT06508788 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of a combination treatment involving a vaginal CO2 laser and a moisturizing niosomal gel for women suffering from genitourinary syndrome of menopause, particularly those with a history of neoplasia where estrogen treatments are contraindicated. The approach aims to provide a non-hormonal therapeutic option to alleviate symptoms associated with this condition. By assessing the outcomes of this combined treatment, the study seeks to determine its potential benefits for this specific patient population.
Who should consider this trial
Good fit: Ideal candidates for this study are women diagnosed with genitourinary syndrome of menopause who have a history of neoplasia and cannot use estrogen therapies.
Not a fit: Patients with concurrent vulvovaginal pathology or significant pelvic organ prolapse may not benefit from this treatment.
Why it matters
Potential benefit: If successful, this treatment could offer a safe and effective alternative for managing genitourinary syndrome symptoms in oncology patients.
How similar studies have performed: While the combination of vaginal laser and moisturizing gel is a novel approach, similar studies have shown promising results in treating genitourinary symptoms with laser therapy.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with an established SGM diagnosis. * Patients with a history of neoplasia in whom the use of estrogens as the first alternative for the treatment of GMS is not recommended. Exclusion Criteria: * Patients with concomitant vulvovaginal pathology. * Patients with a diagnosis of pelvic organ prolapse grade II or greater.
Where this trial is running
L'Hospitalet de Llobregat, Catalonia
- Carlos — L'Hospitalet de Llobregat, Catalonia, Spain (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.